CytoDyn (CYDY) Stock Moves Up: Will The Bounce Back Continue?
The CytoDyn Inc (OTCMKTS:CYDY) stock has seen considerable action this week owing to the events of the week so far but on Thursday, it managed to recover a bit.
The company got a major setback earlier on this week after the United States Food and Drug Administration dished out a public rebuke to CytoDyn and alleged that it had cherry picked data in order to show that its product leronlimab was effective treatment for COVID 19 patients. Following that, the stock had crashed and had recorded declines of as much as 30%. However, on Thursday, the stock managed to mount a recover and went up by 13%.
In this regard, it is necessary to note that CytoDyn also made a key appointment this week and that might have resulted in restoring some degree of confidence among investors.
The company appointed Antonio Migliarese as the new Treasurer and Chief Financial Officer. In this regard, it should be noted that Migliarese had been serving as CytoDyn’s Vice President, Corporate Comptroller prior to this appointment. He will be replacing Michael D. Mulholland, who is going to serve as the vice president of finance at CytoDyn from on.
While this appointment seems to have been welcomed by the market, a bizarre chapter was opened in the company’s current run in with the FDA. Earlier on this week, the Chief Executive Officer of CytoDyn Nader Pourhassan urged the company’s investors to stop badmouthing and trashing the FDA. The statement from the FDA with regards to the clinical trial of leronlimab had clearly not impressed the company’s investors.
The CEO stated that all the badmouthing should be directed at him and requested investors to desist from abusing the agency in any way. The FDA had earlier stated that it had been forced to make a public statement about leronlimab primarily due to the considerable public interest in the product.
International Consolidate (INCC) Stock Almost Doubled This Week: What’s The Buzz?
International Consolidate Companies Inc (OTCMKTS:INCC), better known as INCC, has seen its stock emerge as one of the notable gainers in the past two days. On Wednesday, the INCC stock surged by as much as 31% to takes its gains over the course of the past two trading sessions to 85%.
While the gains made by the INCC stock are impressive, it is also important to point out that there has been no news about the company this week that might have led to such a rally. In this sort of a situation, it could be a good idea for investors to perhaps take a look at a development from earlier on in the month.
Back on May 4, INCC announced that it signed a definitive agreement in order to acquire the assets and businesses of the company Blue Plant Farms LLC. As per the announcement from the company, the deal is expected to be closed on May 30, 2021.
In order to understand the implications of this acquisition, it is important for investors to know a bit more about Blue Plant’s business. The company is involved in the production of CBD products derived from hemp oil and the products are sold under a range of brands.
The products also offer a higher degree of bioavailability since those are produced by deploying Blue Plant’s proprietary water soluble formulas. It goes without saying that it is a significant acquisition for INCC, especially considering the fact that its National Go To Strategy is going to be launched by way of the sale and distribution of products manufactured by Blue Plant.
INCC is going to sign a distribution contract with a convenience store association that boasts of as many as 90000 members. Initially, INCC is trying to take its products to a total of 5000 convenience stores over the course of the next 24 months.
Asia Broadband (AABB) Stock Consolidates Around 15 cents: What Now?
Those who are on the hunt for stocks which might have clocked significant gains so far this year might do well to take a look at the Asia Broadband Inc (OTCMKTS:AABB) stock. It has been one of the major performers so far this year and has managed to deliver gains of 1400%.
While those gains are impressive, it should be noted that on Wednesday, the Asia Broadband stock actually declined by 9%. However, at the same time, experts believe that following the company’s strong performance in the first fiscal quarter, Asia Broadband is now in a position to generate growth in 2021.
The company announced its financial results for the first quarter earlier on this week and the crowning glory of the performance was the $100 million plus in assets that it reported in its balance sheet.
This suggests that Asia Broadband now has the assets and liquidity under its command which will allow it to finance and progress is cryptocurrency and gold mining businesses. Not too long ago, Asia Broadband started selling its gold backed crypto token AABBG and by doing that the company managed to collect as much as $1.5 million in the form of cryptocurrencies alone.
However, that is not all. The company has also designed an international marketing initiative in order to boost its brand, facilitate the sales of more cryptocurrencies and increase the number of transactions through the AABB wallet. Asia Broadband is all set to launch this campaign at some point next week and it could eventually lead to a considerable boost to its cryptocurrency ecosystem.
This campaign is expected to create substantial buzz and also help the company as it progresses the launch of its own cryptocurrency exchange. The company announced recently that is has made meaningful progress with regards to is the crypto exchange and it is one of the stories that investors could consider following closely.
Green Globe International (GGII) Stock Makes a Strong Come back: What’s Next?
If there is one stock that has attracted the attention of investors due to the enormous gains that it has clocked this year so far then it is the Green Globe International (OTCMKTS:GGII) stock.
The Green Globe stock is up by a staggering 29733.33% this year and over the course of the past month alone, it has gone up by 3342.31%. The rally in the stock found new steam on Tuesday and went up once against by as much as 54%. Considering the sort of gains made by the stock, it could be a good move from investors to take a bigger interest in the company.
The company is involved in the marijuana space and is looking to disrupt the tobacco industry. Green Globe is looking to disrupt the multibillion dollar tobacco industry through the introduction of products like herb cigarettes, CBD cigarettes, hemp cigarettes and others. One of the biggest reasons behind the rally in the stock in recent days came about after the company announced that its control has now passed on to The Hempacco Co Inc. Last month Green Globe announced that this was accomplished through the sales of 100 Series A Preferred shares to Hempacco in a private sale back in March.
Once the control of the company passed on to Hempacco, a new board of directors was also installed. The new board is being led by the Chief Executive Officer of Hempacco, Sandro Piancone. In addition to that, it is important to note that Green Globe also applied to the OTC Markets Group for access to the disclosure and information systems. The company is looking to submit any missing reports and also provide information with regards to the new ownership group. The frenetic trading in the stock took off after the announcement and it is now going to be interesting to see if the stock can continue to gain for the rest of this month.
Nsav Holding (NSAV) Stock Resumes Another Round of Rally
The cryptocurrency market might be going through a tough time at this point but the popularity of the industry remains high and hence, there is a lot of interest in companies which are involved in that space. One such company is the United Kingdom based firm Nsav Holding Inc (OTCMKTS:NSAV).
Net Savings is involved in both cryptocurrencies and blockchain and is broadly described as a digital asset technology firm. The Net Savings stock rallied strongly on Tuesday and went up by as much as 60% despite there being no fresh news about the company. However, the rally might be linked to a major announcement from the company last week.
Last week, Net Savings announced that VirtualBroker, a company that it owns, launched its Cryptocurrency Price Search feature. It has been claimed to be a revolutionary feature and is supposed to be one of the most important constituents of the advanced automated non-custodial trading platform.
The particulars of the feature are compelling. The feature offers an interface by way of which VirtualBroker customers will be able to take a look at a range of exchanges and then choose to connect it to their dashboards. Once it is connected, users can easily see the real time price action in cryptocurrencies.
In this regard, it is also necessary to point out the importance of the proprietary High Performance Computing feature from VirtualBroker. This system helps in real time transactions with all the exchanges that have been connected by the user. In addition to that, there is no time lag either.
In this way, it is possible for users to get the best prices after having a look at a large number of exchanges. It seems the market is optimistic about the future of this feature as well considering the latest rally in the stock. Investors could consider keeping an eye on the Net Savings stock this week.
Is HUMBL (HMBL) Stock All Set To Rebound After The Recent Panic?
Up until a few months ago, the HUMBL Inc (OTCMKTS:HMBL) stock was one of the biggest gainers from among penny stocks and had been on the radars of most investors who are interested in penny stock investment.
However, things have not been the same in recent times and it is in this sort of situation in which investors could consider taking a closer look at the HUMBL stock. Last week, there had been no news about the company at all on May 12 but even then the stock suffered from a selloff and the stock tanked by 12%.
The stock has declined sharply and given up as much as 86% since hitting its highest level in 52 weeks. However, despite the decline, it is important to point out that the HUMBL stock is still up by 70% in 2021 so far. The company is engaged in the fast growing digital payments space and is primarily involved in creating mobile apps for the same. In December last year, the company went public by way of a merger with Tesoro Enterprises. Since the merger, the stock had gone on a remarkable rally and emerged as one of the biggest gainers in the market.
The massive rally during that period is possibly the reason why it is falling now. Over the course of the past month, the stock has declined by 66% and by 83% during the past three months. Experts believe that the original rally in the stock earlier on this year had been speculative in nature and the changing trends in the market have resulted in a selloff in HUMBL. It is important to point out that in recent weeks, investors have been winding down their positions in speculative stocks and also in their investments in companies that are dependent on high growth. HUMBL fulfils both those conditions.
CytoDyn Inc (CYDY) Stock Slips Below $2: Time To Buy?
The CytoDyn Inc (OTCMKTS:CYDY) stock went into a meltdown yesterday after the company got a stinging rebuke from the United States Food and Drug Administration.
On Monday, the FDA rebuked CytoDyn for having been selective with regards to the selection data from the two studies of its COVID 19 treatment leronlimab. The FDA alleged that the company tried to show that the product was effective against COVID 19. Both those studies had in fact been failures.
It goes without saying that the development was a major setback for the company and that was reflected in the price action in its stock as well. The CytoDyn stock tanked by as much as 27% yesterday as investors rushed for the exits.
Earlier on this year in March, the Phase 3 clinical trial of leronlimab had been a failure as the product failed to demonstrate its primary target of reducing the effects of symptoms. It failed to meet all the secondary goals as well.
However, CytoDyn decided to turn its focus on 62 seriously ill COVID 19 patients, who had been given mechanical ventilation and concluded that leronlimab helped in reducing all cause mortality by as much as 24%. The company went on to state that the product could also reduce hospitalisation by six days.
The FDA is usually known for being silent when it comes to products which are not approved, but in an unprecedented move the agency dished out a public rebuke to CytoDyn. The agency said that none of the analyses that had been conducted by CytoDyn had been statistically significant.
The agency also stated that the data did not reveal anything that could support the clinical benefits of leronlimab when it comes to the treatment of COVID 19 patients. The agency also stated how clinical trials work which must have come as a further source of embarrassment for CytoDyn.
Northwest Biotherapeutics (NWBO) Stock Makes a Bullish Move: What to Expect Next?
The Northwest Biotherapeutics (OTCMKTS:NWBO) stock was in action in the markets this past Friday and ended up recording gains of as much as 14.50% as investors piled on to it. As a matter of fact, the stock had been in the news ever since Northwest provided an update with regards to its manufacturing facility in the United Kingdom last Wednesday.
In light of the gains made by the stock, it might be a good idea for investors to take a look at the announcement made by Northwest. In addition to that, the company also provided updates with regards to the Phase III trial of its product DCVax, which provides customised immune therapies to patients suffering from cancer tumours.
The company announced that it submitted an application for the certification of its Sawston facility in United Kingdom to Medicines and Healthcare Products Regulatory Agency (MHRA). It emerged that the entire application package for certifying the facility to produce Good Manufacturing Practice (GMP) clinical grade medical products was submitted back on May 7. It is a major milestone for the company considering the fact that it has prepared for this application for more than two years. As a matter of fact, more than a year of those preparations had been conducted under trying conditions during the COVID 19 restriction in the United Kingdom.
Back in March this year, the extent of the preparations made by the company to get the MHRA certification had been detailed as well. It included the physical build-out of the Sawston facility, preparation of batch manufacturing records, building a team of around 40 professionals with the skills to produce Advanced Therapy Medical Products, and developing more than 500 regulatory documents with regards to the operations of the facility. The excitement among investors regarding this development is understandable and it is now going to be interesting to see if the Northwest stock can add to its gains this week.